EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer

Kelsie L Thu iD, Soode Jafari, Jennifer Silvester, Jennifer Cruickshank, Isabel Soria-Bretones, Kelsey Hodgson, Chantal Tobin, Jillian Haight, Asa P Y Lau iD, Tessa Bray, Drew Wakeham, Mark R Bray und 2 weitere

International Journal of Molecular Sciences · 14.03.2026 · 27 (6) · 2665

DOI: 10.3390/ijms27062665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.03.2026. Verfasst von Kelsie L Thu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Toronto, ON M5B 1X3, Canada. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Drug Resistance, Neoplasm, Neoplasm Proteins, Protein Kinase Inhibitors. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, Canada Research Chairs program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR screens are a powerful functional genomics approach for identifying genes that confer sensitivity and resistance to anti-cancer therapies. CFI-402257 (luvixasertib, 2257) is a small molecule inhibitor of threonine tyrosine kinase (TTK), a promising therapeutic target in genomically unstable cancers due to its critical role in establishing the spindle assembly checkpoint (SAC) during mitosis. To inform its ongoing development and evaluation in clinical trials, we sought to use CRISPR activation (i.e., gain of function) screens to identify cellular mechanisms of resistance to 2257 in models of triple-negative breast cancer (TNBC). In vitro screens conducted in two TNBC cell lines nominated ABCG2 as the top resistance-conferring gene in both models. Validation studies assessing clonogenic survival and apoptosis confirmed that ABCG2 overexpression enhanced TNBC resistance to 2257 in vitro, while knockdown enhanced sensitivity. These findings suggest that 2257 is a substrate of ABCG2’s drug efflux activity. However, overexpression of ABCG2 failed to confer resistance to 2257 in TNBC xenografts grown in mice and treated with a moderately active dose and schedule. Our results highlight the potential impact of drug transporters in in vitro CRISPR screens and the importance of confirming the relevance of drug response mechanisms identified in cultured cells using in vivo models that recapitulate drug pharmacokinetics and pharmacodynamics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter, Subfamily G, Member 2Drug Resistance, NeoplasmNeoplasm ProteinsProtein Kinase InhibitorsTriple Negative Breast NeoplasmsProtein Serine-Threonine KinasesClustered Regularly Interspaced Short Palindromic RepeatsHumansFemaleAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysAntineoplastic AgentsApoptosisHeterocyclic Compounds, 4 or More RingsDiketopiperazines

Stichwörter der Autor:innen

ABCG2CFI-402257CRISPR screenbreast cancerdrug resistanceluvixasertib

Substanzen

ATP Binding Cassette Transporter, Subfamily G, Member 2ABCG2 protein, humanNeoplasm ProteinsProtein Kinase Inhibitors3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid…Protein Serine-Threonine KinasesAntineoplastic AgentsHeterocyclic Compounds, 4 or More RingsDiketopiperazines

Autor:innen und Institutionen

  • Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Unity Health Toronto, Toronto, ON M5B 1X3, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 3K3, Canada.
  • Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C4, Canada.
  • Department of Immunology, University of Toronto, Toronto, ON M5S 3K3, Canada.
  • Department of Medical Biophysics, University of Toronto, Toronto, ON M5G 2C4, Canada.
  • Institute of Medical Science, University of Toronto, Toronto, ON M5S 3K3, Canada.

ORCID-Profile: Kelsie L Thu, Asa P Y Lau, Tak W Mak, David W Cescon

Förderung

  • Canadian Institutes of Health Research
  • Canada Research Chairs program

Zitieren

APA

Thu, K. L., Jafari, S., Silvester, J., Cruickshank, J., Soria-Bretones, I., Hodgson, K., Tobin, C., Haight, J., Lau, A. P. Y., Bray, T., Wakeham, D., Bray, M. R., Mak, T. W., & Cescon, D. W. (2026). Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer. International Journal of Molecular Sciences, 27(6), 2665. https://doi.org/10.3390/ijms27062665

Vancouver

Thu KL, Jafari S, Silvester J, Cruickshank J, Soria-Bretones I, Hodgson K, et al. Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer. International Journal of Molecular Sciences. 2026;27(6):2665. doi:10.3390/ijms27062665

BibTeX
@article{Thu2026,
  author = {Thu, Kelsie L and Jafari, Soode and Silvester, Jennifer and Cruickshank, Jennifer and Soria-Bretones, Isabel and Hodgson, Kelsey and Tobin, Chantal and Haight, Jillian and Lau, Asa P Y and Bray, Tessa and Wakeham, Drew and Bray, Mark R and Mak, Tak W and Cescon, David W},
  title = {Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {6},
  pages = {2665},
  doi = {10.3390/ijms27062665}
}
Kostenlos starten →